1 – 47 of 47
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Comparison of dyskinesia profiles after L-DOPA dose challenges with or without dopamine agonist coadministration
(
- Contribution to journal › Article
-
Mark
Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Distinctive Effects of D1 and D2 Receptor Agonists on Cortico-Basal Ganglia Oscillations in a Rodent Model of L-DOPA-Induced Dyskinesia
(
- Contribution to journal › Article
- 2021
-
Mark
Parkinson's Disease with Device, Diary, or in Disguise. Dyskinesia reduction, motor state evaluation, and workforce participation among persons with Parkinson's disease.
2021) In Lund University Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
-
Mark
Validation and clinical value of the MANAGE-PD tool : A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications
(
- Contribution to journal › Article
- 2020
-
Mark
The role of glia in Parkinson's disease : Emerging concepts and therapeutic applications
(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2019
-
Mark
Significance and translational value of high-frequency cortico-basal ganglia oscillations in Parkinson's disease
(
- Contribution to journal › Article
- 2018
-
Mark
Circuit-level analyses of cortico-basal ganglia-thalamic networks. Effects of dopamine dysregulation and experience dependent plasticity.
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Neurophysiological effects in cortico-basal ganglia-thalamic circuits of antidyskinetic treatment with 5-HT1A receptor biased agonists
(
- Contribution to journal › Article
-
Mark
The serotonergic system in L-DOPA-induced dyskinesia : pre-clinical evidence and clinical perspective
(
- Contribution to journal › Article
-
Mark
Animal models of l-DOPA-induced dyskinesia : the 6-OHDA-lesioned rat and mouse
(
- Contribution to journal › Article
-
Mark
Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease : a multi-country Delphi-panel approach
(
- Contribution to journal › Article
- 2017
-
Mark
BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats
(
- Contribution to journal › Article
-
Mark
Infusional Therapies, Continuous Dopaminergic Stimulation, and Nonmotor Symptoms
(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
CK2 oppositely modulates L-DOPA-induced dyskinesia via striatal projection neurons expressing D1 or D2 receptors
(
- Contribution to journal › Article
- 2016
-
Mark
The Role of the Cortico-Basal Ganglia-System in Voluntary Movements
(
- Thesis › Doctoral thesis (compilation)
- 2015
-
Mark
Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: Final 12-Month, Open-Label Results
(
- Contribution to journal › Article
- 2013
-
Mark
Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care
(
- Contribution to journal › Article
-
Mark
Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia
(
- Contribution to journal › Article
-
Mark
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia
(
- Contribution to journal › Article
-
Mark
mTOR Inhibition Alleviates L-DOPA-Induced Dyskinesia in Parkinsonian Rats
(
- Contribution to journal › Article
- 2012
-
Mark
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to l-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels
(
- Contribution to journal › Article
- 2011
-
Mark
Microvascular plasticity and neurovascular coupling in the pharmacotherapy of Parkinson's disease
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease
(
- Contribution to journal › Article
-
Mark
Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate 1-DOPA-induced dyskinesia
(
- Contribution to journal › Article
- 2010
-
Mark
Neural grafting in Parkinson's disease: unraveling the mechanisms underlying graft-induced dyskinesia
(
- Contribution to journal › Scientific review
-
Mark
Modeling pathophysiological aspects of Parkinson’s disease: Manipulating DA handling and alpha-synuclein expression in the nigrostriatal pathway using viral vectors
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Involvement of non-dopaminergic systems in L-DOPA-induced dyskinsia
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias
(
- Contribution to journal › Article
-
Mark
Dyskinesia - Advances in the understanding of pathophysiology and possible treatment options
(
- Contribution to journal › Article
- 2009
-
Mark
Chronic intermittent L-DOPA treatment induces changes in dopamine release
(
- Contribution to journal › Article
-
Mark
Presynaptic mechanisms in L-DOPA-induced dyskinesia
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Gene therapy by enzyme replacement for Parkinson’s disease Optimization of continuous DOPA delivery and development of a candidate vector for clinical application
(
- Thesis › Doctoral thesis (compilation)
- 2008
-
Mark
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
(
- Contribution to journal › Article
- 2007
-
Mark
Expression pattern of JunD after acute or chronic l-DOPA treatment: Comparison with DeltaFosB.
(
- Contribution to journal › Article
-
Mark
Proteomic analysis of striatal proteins in the rat model of l-DOPA-induced dyskinesia.
(
- Contribution to journal › Article
-
Mark
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.
(
- Contribution to journal › Article
- 2006
-
Mark
Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia.
(
- Contribution to journal › Article
-
Mark
Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia.
(
- Contribution to journal › Article
- 2005
-
Mark
Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors.
(
- Contribution to journal › Article
- 2004
-
Mark
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia
(
- Contribution to journal › Article
-
Mark
Modelling parkinsonian akinesia and dyskinesia in dopamine depleted rodents
2004)(
- Thesis › Doctoral thesis (compilation)
-
Mark
Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy)
(
- Contribution to journal › Article
- 2003
-
Mark
Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment.
(
- Contribution to journal › Article
-
Mark
Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia.
(
- Contribution to journal › Article
-
Mark
Transcriptional dysregulation in L-DOPA-induced dyskinesia
2003)(
- Thesis › Doctoral thesis (compilation)
- 2002
-
Mark
Toward a restorative therapy for Parkinson´s disease. Studies on the functional efficacy of intracerebral fetal cell transplants and GDNF delivery.
2002)(
- Thesis › Doctoral thesis (compilation)